




NuPathe to Present at the Roth 23rd Annual OC Growth Stock Conference
CONSHOHOCKEN, PA--(Marketwire - March 11, 2011) - NuPathe Inc. (
A live audio webcast of the presentation will be available via the "Investor Relations" page of the NuPathe website, [ www.nupathe.com ]. Please log on through NuPathe's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will also be archived on the Company's website for 90 days following the call.
About NuPathe
NuPathe Inc. ([ www.nupathe.com ]) is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, [ Zelrix ], is a single-use, transdermal sumatriptan patch being developed for the treatment of acute migraine. In addition to Zelrix, NuPathe has two proprietary product candidates in preclinical development: [ NP201 ] for the continuous symptomatic treatment of Parkinson's disease, and [ NP202 ] for the long-term treatment of schizophrenia and bipolar disorder.